Coeptis Therapeutics Hldgs I
13F holders, Q4 2025 (December 31)14holders +4
6new positions
2sold out
$14.25avg. 13F price*
At the end of Q4 2025, 14 institutions reported holding Coeptis Therapeutics Hldgs I in their 13F filings, up 4 from Q3 2025. 6 opened new positions and 2 sold out. The largest holders were Vanguard Group Inc. ($4.8M), Geode Capital Management, LLC ($600K) and State Street Corp. ($382K).
- Company
- Coeptis Therapeutics Hldgs I
- CUSIP
- 19207A207
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $631K |
| Exits | 2 | $463K |
All 13F filers, Q3 2025 → Q4 2025: 347,268 shares bought and 26,725 shares sold, net +320,543 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| Vanguard Group Inc. | 0.00% | Add +569.9% | 339,486 | $4.8M |
| Geode Capital Management, LLC | 0.00% | Add +12.6% | 42,097 | $600K |
| State Street Corp. | 0.00% | Add +35.0% | 26,830 | $382K |
| Marshall Wace, LLP | 0.00% | New | 18,192 | $259K |
| BlackRock, Inc. | 0.00% | New | 13,566 | $193K |
| Northern Trust Corp. | 0.00% | New | 12,219 | $174K |
| Steward Partners Investment Advisory, LLC | 0.00% | Add +100.0% | 5,000 | $71K |
| PNC Financial Services Group, Inc. | 0.00% | Reduce -48.6% | 238 | $3K |
| Morgan Stanley | 0.00% | No change | 200 | $3K |
| UBS Group AG | 0.00% | New | 193 | $3K |
| Osaic Holdings, Inc. | 0.00% | New | 100 | $1K |
| Bank of America Corp. | 0.00% | Add +2.9% | 36 | $513 |
| Barclays PLC | 0.00% | No change | 3 | $43 |
| SageView Advisory Group, LLC | 0.00% | New | 3 | $43 |
"% of holder's portfolio" is COEPTIS THERAPEUTICS HLDGS I's weight in each manager's 13F, not the share of Coeptis Therapeutics Hldgs I the manager owns.